轻度 SARS-CoV-2 感染一年后的抗体反应。
Antibody Responses One Year after Mild SARS-CoV-2 Infection.
机构信息
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
出版信息
J Korean Med Sci. 2021 May 31;36(21):e157. doi: 10.3346/jkms.2021.36.e157.
Abstract
Understanding the long-term kinetics of antibodies in coronavirus disease 2019 (COVID-19) is essential in interpreting serosurvey data. We investigated the antibody response one year after infection in 52 mildly symptomatic patients with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, using three commercial immunoassays and a surrogate virus neutralization test (sVNT) kit. Anti-N pan-immunoglobulin (Ig), anti-S IgG, and anti-S1 IgG were detected in 43 (82.7%), 44 (84.6%), and 30 (57.7%), respectively. In 49 (94.2%), the antibody could be detected by either anti-N pan-Ig or anti-S IgG assay. In the sVNT, 30 (57.7%) had positive neutralizing activity. Despite waning immunity, SARS-CoV-2 antibodies can be detected up to one year after infection, even in mild COVID-19 patients.
摘要
了解 2019 年冠状病毒病（COVID-19）抗体的长期动力学对于解释血清学调查数据至关重要。我们使用三种商业免疫测定法和一种替代病毒中和试验（sVNT）试剂盒，对 52 例有症状的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染轻度症状患者，在感染一年后进行了抗体反应研究。分别有 43 例（82.7%）、44 例（84.6%）和 30 例（57.7%）检测到抗-N 泛免疫球蛋白（Ig）、抗-S IgG 和抗-S1 IgG。在 49 例（94.2%）中，通过抗-N 泛 Ig 或抗-S IgG 测定均可检测到抗体。在 sVNT 中，有 30 例（57.7%）具有阳性中和活性。尽管免疫应答减弱，但在感染一年后仍可检测到 SARS-CoV-2 抗体，即使是在 COVID-19 轻症患者中也是如此。
相似文献
1
Antibody Responses One Year after Mild SARS-CoV-2 Infection.
J Korean Med Sci. 2021 May 31;36(21):e157. doi: 10.3346/jkms.2021.36.e157.
2
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
Viruses. 2021 Apr 16;13(4):697. doi: 10.3390/v13040697.
3
Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection.
Emerg Infect Dis. 2021 Jan;27(1):327-9. doi: 10.3201/eid2701.203515. Epub 2020 Oct 13.
4
Clinical significance of SARS-CoV-2-specific IgG detection with a rapid antibody kit for COVID-19 patients.
Influenza Other Respir Viruses. 2021 Jan;15(1):13-18. doi: 10.1111/irv.12802. Epub 2020 Sep 10.
5
Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
J Clin Microbiol. 2021 Apr 20;59(5). doi: 10.1128/JCM.02890-20.
6
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Pediatrics. 2020 Dec;146(6). doi: 10.1542/peds.2020-018242. Epub 2020 Sep 2.
7
Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection.
Emerg Infect Dis. 2021 Mar;27(3):928-931. doi: 10.3201/eid2703.204543. Epub 2020 Dec 22.
8
Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients.
Viral Immunol. 2021 Apr;34(3):201-209. doi: 10.1089/vim.2020.0321. Epub 2021 Mar 3.
9
SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays.
Viruses. 2021 Feb 4;13(2):247. doi: 10.3390/v13020247.
10
Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
Clin Microbiol Infect. 2021 Mar;27(3):470.e1-470.e9. doi: 10.1016/j.cmi.2020.11.009. Epub 2020 Nov 20.
引用本文的文献
1
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.
Wellcome Open Res. 2024 Dec 2;8:350. doi: 10.12688/wellcomeopenres.19414.2. eCollection 2023.
2
Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study.
J Clin Med. 2024 Jan 29;13(3):762. doi: 10.3390/jcm13030762.
3
Persistent humoral and CD4 T cell immunity after mild SARS-COV-2 infection-The CoNAN long-term study.
Front Immunol. 2023 Jan 13;13:1095129. doi: 10.3389/fimmu.2022.1095129. eCollection 2022.
4
The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios.
J Pers Med. 2022 Oct 23;12(11):1756. doi: 10.3390/jpm12111756.
5
Would New SARS-CoV-2 Variants Change the War against COVID-19?
Epidemiologia (Basel). 2022 Apr 29;3(2):229-237. doi: 10.3390/epidemiologia3020018.
6
Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses.
Front Immunol. 2022 Aug 5;13:864278. doi: 10.3389/fimmu.2022.864278. eCollection 2022.
7
High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020-2021.
Front Med (Lausanne). 2022 Jul 28;9:876532. doi: 10.3389/fmed.2022.876532. eCollection 2022.
8
Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection.
JAMA Netw Open. 2022 Jul 1;5(7):e2221616. doi: 10.1001/jamanetworkopen.2022.21616.
9
Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection.
BMC Med. 2022 May 4;20(1):181. doi: 10.1186/s12916-022-02383-4.
10
Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre.
Indian J Med Microbiol. 2022 Apr-Jun;40(2):200-203. doi: 10.1016/j.ijmmb.2022.03.003. Epub 2022 Apr 11.
本文引用的文献
1
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
2
The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709. doi: 10.1093/cid/ciab004.
3
Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection.
Emerg Infect Dis. 2021 Mar;27(3):928-931. doi: 10.3201/eid2703.204543. Epub 2020 Dec 22.
4
Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020.
MMWR Morb Mortal Wkly Rep. 2020 Nov 27;69(47):1762-1766. doi: 10.15585/mmwr.mm6947a2.
5
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
Immunity. 2020 Nov 17;53(5):925-933.e4. doi: 10.1016/j.immuni.2020.10.004. Epub 2020 Oct 14.
6
Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection.
Emerg Infect Dis. 2021 Jan;27(1):327-9. doi: 10.3201/eid2701.203515. Epub 2020 Oct 13.
7
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
8
Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients.
Emerg Infect Dis. 2020 Oct;26(10):2484-2487. doi: 10.3201/eid2610.202211. Epub 2020 Jun 24.
9
Selecting coronavirus disease 2019 patients with negligible risk of progression: early experience from non-hospital isolation facility in Korea.
Korean J Intern Med. 2020 Jul;35(4):765-770. doi: 10.3904/kjim.2020.159. Epub 2020 May 29.
10
Duration of antibody responses after severe acute respiratory syndrome.
Emerg Infect Dis. 2007 Oct;13(10):1562-4. doi: 10.3201/eid1310.070576.
Zotero 插件